MedTrace Logo

Protection of Rectum From High Radiation Doses

NCT01601691 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-11-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the usefulness of diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low dose brachytherapy.

Conditions

Interventions

DEVICE

DuraSeal

Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate

Sponsors & Collaborators

  • Oulu University Hospital

    collaborator OTHER

  • University of Oulu

    lead OTHER

Principal Investigators

  • Markku Vaarala, MD, PhD · Oulu Univeristy Hospital

  • Merja Korpela, MD · Oulu University Hospital

  • Vesa-Pekka Heikkilä, FL · Oulu University Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
76 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-01-31
Completion
2013-03-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601691 on ClinicalTrials.gov